MARKET

AXGN

AXGN

Axogen Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.36
-0.76
-5.81%
Opening 11:28 09/21 EDT
OPEN
12.90
PREV CLOSE
13.12
HIGH
12.90
LOW
12.18
VOLUME
108.39K
TURNOVER
--
52 WEEK HIGH
18.84
52 WEEK LOW
7.16
MARKET CAP
495.34M
P/E (TTM)
-16.9350
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Arrowhead Pharmaceuticals, Myomo leads healthcare gainers, Novus Therapeutics, Jounce Therapeutics among major losers
Gainers: Arrowhead Pharmaceuticals (ARWR) +46%, Myomo (MYO) +38%, AxoGen (AXGN) +15%, Covetrus (CVET) +14%, Inovio Pharmaceuticals (INO) +13%.Losers: Novus Therapeutics (NVUS) -13%, Jounce Therapeutics (JNCE) -10%, Syneos Health (SYNH) -7%, Verastem (VSTM) -5%, Evogene (EVGN) -5%.
Seekingalpha · 5d ago
Axogen, Inc. to Present at the Cantor Virtual Global Healthcare Conference
ALACHUA, Fla., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Cantor Virtual
GlobeNewswire · 08/31 12:00
AxoGen (AXGN) Reports Q2 Loss, Tops Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of 40.00% and 5.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/05 23:45
Axogen, Inc. Reports Second Quarter 2020 Financial Results
ALACHUA, Fla., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the second quart
GlobeNewswire · 08/05 20:01
Earnings Preview: AxoGen (AXGN) Q2 Earnings Expected to Decline
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/29 16:33
Axogen, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
ALACHUA, Fla., July 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and pre
GlobeNewswire · 07/29 11:00
BioNTech COVID-19 Progress, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/23 14:43
Axogen concludes enrollment in late-stage nerve graft study
Axogen (NASDAQ:AXGN) has completed patient enrollment in its Phase 3 (RECON) study for Avance Nerve Graft. The 220-subject study compares the graft to manu
seekingalpha · 07/22 18:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AXGN stock price target is 16.30 with a high estimate of 22.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 201
Institutional Holdings: 45.10M
% Owned: 112.52%
Shares Outstanding: 40.08M
TypeInstitutionsShares
Increased
47
3.86M
New
47
-4.21M
Decreased
17
485.41K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-2.47%
Healthcare Equipment & Supplies
-2.29%
Key Executives
Chairman/President/Chief Executive Officer/Director
Karen Zaderej
Chief Financial Officer
Peter Mariani
Chief Human Resource Officer
Maria Martinez
Chief Compliance Officer/General Counsel
Brad Ottinger
Vice President - Operations
Mike Donovan
Vice President
Erick DeVinney
Vice President
Mark Friedman
Vice President - Research & Development
Angelo Scopelianos
Other
Isabelle Billet
Other
Eric Sandberg
Lead Director/Independent Director
Amy Wendell
Director
Gregory Freitag
Independent Director
Quentin Blackford
Independent Director
Mark Gold
Independent Director
Alan Levine
Independent Director
Mark Stephen Gold
Independent Director
Guido Neels
Independent Director
Robert Rudelius
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
12/21/2009
Dividend USD 1
01/27/2010
--
Dividend USD 0.06
02/23/2005

Analyst Price Target

The average AXGN stock price target is 16.30 with a high estimate of 22.00 and a low estimate of 13.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AXGN
AxoGen, Inc. offers surgical solutions for peripheral nerve injuries. The Company provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. Its portfolio of products includes Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector and Avive Soft Tissue Membrane. Along with these core surgical products, the Company also offers the AxoTouch Two-Point Discriminator, and AcroVal Neurosensory and Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation; assessing return of sensory, grip and pinch function; evaluating treatment interventions, and providing feedback to patients on nerve function. Its portfolio of products is available in the United States, Canada, the United Kingdom and several European and other countries. The Company's products are used by surgeons during surgical interventions to repair a range of nerve injuries throughout the body.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of AxoGen Inc stock information, including NASDAQ:AXGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AXGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AXGN stock methods without spending real money on the virtual paper trading platform.